ModiQuest Research and Cellectis to Collaborate
News Mar 07, 2015
ModiQuest Research BV has announced that it has entered into a collaboration with Cellectis aimed at the generation of novel monoclonal antibodies against Cellectis’ target(s).
During the collaboration, ModiQuest may make use of its proprietary electrofusion technology, ModiFuse™. Financial details of the collaboration were not disclosed.
“We are pleased that Cellectis has selected ModiQuest Research as a development partner for its activities,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “This collaboration once more demonstrates the value of our broad and unique antibody generation platform and we are delighted to work together with Cellectis in the emerging field of cancer immunotherapy.”
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE